SCHEDULE: Suvretta Capital, Averill Master Fund Boost Compass Therapeutics Stake

Suvretta Capital Management, Averill Master Fund, and Aaron Cowen have collectively reported significant beneficial ownership in Compass Therapeutics, Inc., with Suvretta and Cowen each holding 8.2% and Averill holding 7.1% of common stock.

Summary

• Suvretta Capital Management, LLC, Averill Master Fund, Ltd., and Aaron Cowen have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership of Compass Therapeutics, Inc. Common Stock.
• Suvretta Capital Management, LLC and Aaron Cowen each beneficially own 14,101,159 shares, representing 8.2% of the class.
• Averill Master Fund, Ltd. beneficially owns 12,229,050 shares, representing 7.1% of the class.
• All reported shares are held with shared voting and shared dispositive power by the respective reporting persons.
• Aaron Cowen is identified as the control person for Suvretta Capital Management, LLC.
• Averill Master Fund, Ltd. is an advisory client of Suvretta Capital Management, LLC and is known to beneficially own more than 5% of the Common Stock.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates significant institutional and individual ownership, which can be viewed as a positive signal of investor confidence, though it does not provide operational or financial performance details.

Positives

• Increased transparency regarding significant institutional and individual ownership in Compass Therapeutics, Inc.
• The substantial stake held by Suvretta Capital Management, a notable investment adviser, may signal confidence in the company's long-term prospects.

Risks

• The concentration of ownership by a few entities could potentially influence future corporate decisions, although the filing states the shares were not acquired to change or influence control.

Future Outlook

NA

Industry Context

This filing provides insight into the ownership structure of Compass Therapeutics, Inc., a biotechnology company. Significant institutional ownership, as disclosed in this Schedule 13G, is a common feature in the biotech sector, where investment firms often take substantial positions in companies with promising drug pipelines or technologies.

Stakeholder Impact

• Shareholders: Provides transparency on significant ownership stakes, which can influence market perception and potentially future stock liquidity.
• Investment Professionals: Offers data points on institutional interest and positioning in Compass Therapeutics, Inc.

Key Dates

Keywords

Compass Therapeutics, Suvretta Capital Management, Averill Master Fund, Aaron Cowen, Beneficial Ownership, Schedule 13G, Institutional Ownership, Biotechnology, Investment, SEC Filing